UY32750A - IMIDAZOLS REPLACED AND USE OF THE SAME - Google Patents

IMIDAZOLS REPLACED AND USE OF THE SAME

Info

Publication number
UY32750A
UY32750A UY0001032750A UY32750A UY32750A UY 32750 A UY32750 A UY 32750A UY 0001032750 A UY0001032750 A UY 0001032750A UY 32750 A UY32750 A UY 32750A UY 32750 A UY32750 A UY 32750A
Authority
UY
Uruguay
Prior art keywords
imidazols
replaced
same
beta
limited
Prior art date
Application number
UY0001032750A
Other languages
Spanish (es)
Inventor
Viklund Jenny
Gravenfors Ylva
Kolmodin Karin
Blid Jan
Ginman Tobias
Britt-Marie Swahn
Jacob Kihlstroem
Johan Lindstroem
Sofia Karlstroem
Rahm Frederik
Frederik Von Kieseritzky
Stefan Von Berg
Marie Sundstroem
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY32750A publication Critical patent/UY32750A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de fórmula (I) y sus composiciones farmacéuticas. Además, la presente invención se refiere a métodos terapéuticos para el tratamiento y/o prevención de patologías relacionadas con AB(beta) tales como síndrome de Down, angiopatía B(beta) amiloide tal como pero sin limitarse a angiopatía amiloide cerebral o hemorragia cerebral hereditaria, trastornos asociados con el deterioro cognitivo tal como pero sin limitarse a deterioro cognitivo leve (MCI, por su sigla inglés) y enfermedad de Alzheimer.The present invention relates to new compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and / or prevention of diseases related to AB (beta) such as Down syndrome, amyloid B (beta) angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage. , disorders associated with cognitive impairment such as but not limited to mild cognitive impairment (MCI) and Alzheimer's disease.

UY0001032750A 2009-07-02 2010-07-01 IMIDAZOLS REPLACED AND USE OF THE SAME UY32750A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22253509P 2009-07-02 2009-07-02

Publications (1)

Publication Number Publication Date
UY32750A true UY32750A (en) 2011-01-31

Family

ID=43411290

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032750A UY32750A (en) 2009-07-02 2010-07-01 IMIDAZOLS REPLACED AND USE OF THE SAME

Country Status (4)

Country Link
AR (1) AR077365A1 (en)
TW (1) TW201103893A (en)
UY (1) UY32750A (en)
WO (1) WO2011002408A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108363C2 (en) 2009-10-08 2015-04-27 IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US20120165346A1 (en) * 2010-12-22 2012-06-28 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9650336B2 (en) 2011-10-10 2017-05-16 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US10548882B2 (en) * 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
CN114989103A (en) * 2022-06-09 2022-09-02 杭州科巢生物科技有限公司 Preparation method of 2-methoxy-3- (1-methyl-1H-1, 2, 4-triazole-3-yl) aniline

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176850A1 (en) * 2005-11-21 2009-07-09 Astrazeneca Ab Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia
TW200734311A (en) * 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
WO2008076043A1 (en) * 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5,5-diaryl-imidazol-4-ones
TW200831484A (en) * 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200902503A (en) * 2007-05-15 2009-01-16 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
WO2011002408A1 (en) 2011-01-06
AR077365A1 (en) 2011-08-24
TW201103893A (en) 2011-02-01

Similar Documents

Publication Publication Date Title
UY32750A (en) IMIDAZOLS REPLACED AND USE OF THE SAME
UY32751A (en) IMIDAZOLS REPLACED AND USE OF THE SAME
CR20130308A (en) COMPOUNDS AND ITS USE AS BACE INHIBITORS
CR20110255A (en) NEW COMPOUNDS 578
CO6290683A2 (en) HETEROCICLIC IMIDAZOLINE PIRIDO COMPOUNDS AND THEIR COMPOSITIONS AS C-MET INHIBITORS
GT200900294A (en) AMINO-HETEROCYCLIC COMPOUNDS
ECSP11010754A (en) USEFUL TRIAZOL DERIVATIVES FOR THE TREATMENT OF DISEASES
UY35612A (en) BICYCLIC SULFONAMIDE COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS
DOP2012000067A (en) IMINOTIADIAZINE DIOXIDE COMPOUNDS AS BETA SITE APP DISOCIATION ENZYME INHIBITORS (BACE), COMPOSITIONS, AND ITS USE
CL2007001887A1 (en) COMPOUNDS DERIVED FROM BIFENSUSTUIDAS BY TETRAZOL; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P2X PURINERGIC RECEPTORS, SUCH AS GASTROINT DISORDERS
ECSP13013048A (en) SPIRO- [1,3] -OXACINES AND SPIRO- [1,4] -OXACEPINS AS INHIBITORS
MX2013004307A (en) Arylamide derivatives as ttx-s blockers.
CL2008003591A1 (en) Compounds derived from substituted isoxazolo-pyridine; preparation procedure; pharmaceutical composition; and its use in the treatment of cognitive disorders and Alzheimer's, mediated by binding to the alpha 5-gaba receptor binding site.
CR20130588A (en) HALOGENOALQUIL-1,3-OXAZINAS AS INHIBITORS OF THE BACE1 AND / OR BACE 2
ECSP109904A (en) ANTIVIRAL COMPOUNDS
CR20140071A (en) NEW 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKIRASA INHIBITORS
UY32622A (en) NEW COMPOUNDS FOR THE TREATMENT OF PATHOLOGIES RELATED TO AB (BETA)
ECSP14027564A (en) AGENTS TO TREAT DISORDERS INVOLVING RIANODINE RECEPTOR MODULATION
CL2014001838A1 (en) Compounds derived from fluormethyl-5,6-dihydro-4h- [1,3] oxazin-2-ylamine, as bace1 inhibitors; its process of obtaining; pharmaceutical composition that contains them; and its use for the therapeutic and / or prophylactic treatment of Alzheimer's disease, amyotrophic lateral sclerosis, cancer, cardiovascular diseases and gastrointestinal diseases, among others.
CL2012001461A1 (en) Compounds derived from diphenyl-pyrazolopyridines, modulators of the nuclear receptor nurr-1; intermediate compounds; pharmaceutical composition; and its use for the treatment and prevention of neurodegenerative diseases, brain trauma, inflammatory diseases, osteoporosis, cancer, among others.
ECSP088807A (en) TETRAHYDRO-PYRIMIDOAZEPINS AS MODULATORS OF THE TRANSITORY POTENTIAL RECEIVER OF VAILLINOID 1 (TRPV1)
IN2014MN01982A (en)
DOP2011000134A (en) WE REACT AS BETA SECRETASA INHIBITORS
IN2014MN02056A (en)
CL2011000865A1 (en) Isoquinolinone derived compounds; pharmaceutical composition comprising them; and use of the compound to treat diseases such as psychosis, schizophrenia, Alzheimer's among others.

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20130125